Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Subscribe To Our Newsletter & Stay Updated